Contineum Therapeutics Q3 Net Loss Widens 46% to $18.7 Million

Bitget2026/11/03 21:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Contineum Therapeutics’ third-quarter 2026 net loss widened 46% year over year to $18.7 million.
Research and development expenses rose 45% to $16 million, driven by higher PIPE-791 IPF program expenses and employee-related costs.
Cash, cash equivalents and marketable securities totaled $244.5 million at September 30, supporting projected operations through mid-2029.
The Phase 2 PROPEL-IPF trial expanded to more than 100 sites across 16 countries to support enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611031605BIZWIRE_USPR_____20261103_BW547642) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Contineum Therapeutics Q3 Net Loss Widens 46% to $18.7 Million

You may also like

Crypto prices